PDF: Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib

PDF Download: Health Canada approved selumetinib in 2022 for treating inoperable plexiform neurofibromas in children with neurofibromatosis type 1. Clinical trials showed 74% of patients experienced significant tumor shrinkage, with improvements in pain and quality of life. The oral MEK inhibitor offers the first targeted therapy for these historically difficult-to-treat nerve tumors.
Read online:
Therapeutic Advances in Neurofibromatosis Type 1: A Focus on Selumetinib